Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | TLR4 | O00206 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16160401 | 1.00 | CYP1A2 (0.54) | CYP1A2ALDH1A1L3MBTL1NOS1NOS2 | |
| SCHEMBL9147219 | 0.98 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1NOS1NOS2 | |
| SCHEMBL11009926 | 0.98 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1NOS1NOS2 | |
| SCHEMBL5228161 | 0.98 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1NOS1NOS2 | |
| SCHEMBL3323738 | 0.98 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1NOS1NOS2 | |
| SCHEMBL10719856 | 0.98 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1NOS1NOS2 | |
| SCHEMBL18800105 | 0.98 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1NOS1NOS2 | |
| SCHEMBL14862830 | 0.98 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1NOS1NOS2 | |
| SCHEMBL7804803 | 0.95 | CYP1A2 (0.50) | CYP1A2ALDH1A1L3MBTL1NOS1NOS2 | |
| SCHEMBL7741474 | 0.95 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10118169-B2 | Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis | THE UNIVERSITY OF CHICAGO (US) | 2018-11-06 | — | — | US | disclosed |
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-22 | — | — | US | disclosed |
| US-7119115-B2 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | US | disclosed |
| EP-1414805-A1 | INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY | Aventis Pharma S.A. (FR) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011833-A1 | INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY | AVENTIS PHARMA S.A. (FR) | 2003-02-13 | — | — | WO | disclosed |
| US-6410748-B1 | Alicycli c group-containing monomer | KABUSHIKI KAISHA TOSHIBA (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6291129-B1 | LIGHT SENSITIVE ELEMENT WITH UNSATURATED POLYMERS | KABUSHIKI KAISHA TOSHIBA (JP) | 2001-09-18 | — | — | US | disclosed |
| US-4873019-A | LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | POF1B, FGFR1, COASY | CYP1A2 1613/4885ALDH1A1 861/4885L3MBTL1 4128/4885 |
| US-10118169-B2 | Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis | POF1B, FGFR1, COASY | CYP1A2 1613/4885ALDH1A1 861/4885L3MBTL1 4128/4885 |
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | IDO1, IDO2, INMT | CYP1A2 12/4885ALDH1A1 166/4885L3MBTL1 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.